VICO — Vicore Pharma Holding AB Share Price
0.000.00%
Last trade - 00:00- SEK1.82bn
- SEK1.34bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4 | ||
| Price to Tang. Book | 4.02 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -70.37% | ||
| Return on Equity | -83.53% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | SEKm | n/a | n/a | n/a | n/a | n/a | 34.67 | n/a | -100% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Directors
- Michael Jensen NEC (50)
- Carl-Johan Dalsgaard CEO (65)
- Hans Jeppsson CFO
- Nina Carlen CAD
- Rohit Batta CMO
- Elin Rosendahl VPR
- Johanna Grans OTH
- Johan Raud OTH
- Jacob Gunterberg IND (54)
- Heidi Hunter IND (63)
- Maarten Kraan IND (60)
- Sara Malcus IND (46)
- Hans Schikan IND (63)
- Peter Strom IND (69)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- May 10th, 2005
- Public Since
- December 10th, 2015
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- OMX Nordic Exchange Stockholm
- Shares in Issue
- 111,722,979
- Address
- Kornhamnstorg 53, STOCKHOLM, 111 27
- Web
- https://vicorepharma.com/
- Phone
- +46 317880560
- Contact
- Ahmed Mousa
- Auditors
- Ernst & Young AB
Upcoming Events for VICO
Vicore Pharma Holding AB Annual Shareholders Meeting
Vicore Pharma Holding AB Annual Shareholders Meeting
Q2 2024 Vicore Pharma Holding AB Earnings Release
Similar to VICO
2cureX AB
OMX Nordic Exchange Stockholm
Abliva AB
OMX Nordic Exchange Stockholm
Acousort AB
OMX Nordic Exchange Stockholm
Active Biotech AB publ
OMX Nordic Exchange Stockholm
AddLife AB
OMX Nordic Exchange Stockholm
FAQ
What is the Vicore Pharma Holding AB share price?
As of Today at 19:23 UTC, shares in Vicore Pharma Holding AB are trading at SEK16.32. This share price information is delayed by 15 minutes.
How has the Vicore Pharma Holding AB share price performed this year?
Shares in Vicore Pharma Holding AB last closed at SEK16.32 and the price had moved by -15.35% over the past 365 days. In terms of relative price strength the Vicore Pharma Holding AB share price has underperformed the FTSE Global All Cap Index by -20.53% over the past year.
What are the analyst and broker recommendations for Vicore Pharma Holding AB?
The overall consensus recommendation for Vicore Pharma Holding AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Vicore Pharma Holding AB dividend yield?
Vicore Pharma Holding AB does not currently pay a dividend.
Does Vicore Pharma Holding AB pay a dividend?
Vicore Pharma Holding AB does not currently pay a dividend.
When does Vicore Pharma Holding AB next pay dividends?
Vicore Pharma Holding AB does not currently pay a dividend.
How do I buy Vicore Pharma Holding AB shares?
To buy shares in Vicore Pharma Holding AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Vicore Pharma Holding AB?
As of the previous close price of SEK16.32, shares in Vicore Pharma Holding AB had a market capitalisation of SEK1.82bn.
Where are Vicore Pharma Holding AB shares listed?
Here are the trading details for Vicore Pharma Holding AB:
- Country of listing: Sweden
- Exchange: STO
- Ticker Symbol: VICO
What kind of share is Vicore Pharma Holding AB?
Based on an overall assessment of its quality, value and momentum Vicore Pharma Holding AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Vicore Pharma Holding AB share price forecast for 2024?
The analyst consensus target price for shares in Vicore Pharma Holding AB is SEK56.50. That is 246.2% above the last closing price of SEK16.32.
Analysts covering Vicore Pharma Holding AB currently have a consensus Earnings Per Share (EPS) forecast of -SEK1.51 for the next financial year.
What is the trend in the Vicore Pharma Holding AB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Vicore Pharma Holding AB. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -0.31%.
As of the last closing price of SEK16.32, shares in Vicore Pharma Holding AB were trading +9.05% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Vicore Pharma Holding AB PE Ratio?
The Vicore Pharma Holding AB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at SEK16.32.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Vicore Pharma Holding AB?
Vicore Pharma Holding AB's management team is headed by:
- Michael Jensen - NEC
- Carl-Johan Dalsgaard - CEO
- Hans Jeppsson - CFO
- Nina Carlen - CAD
- Rohit Batta - CMO
- Elin Rosendahl - VPR
- Johanna Grans - OTH
- Johan Raud - OTH
- Jacob Gunterberg - IND
- Heidi Hunter - IND
- Maarten Kraan - IND
- Sara Malcus - IND
- Hans Schikan - IND
- Peter Strom - IND